中新集團(601512.SH):醫療叁號基金已完成備案手續並取得備案證明
格隆匯 6 月 19日丨中新集團(601512.SH)公佈,2020年2月7日,公司第四屆董事會第四十四次會議審議通過《關於公司參與投資設立蘇州工業園區元禾原點智能叁號、醫療叁號基金暨關聯交易的議案》,公司計劃參與投資由蘇州工業園區原點治則創業投資管理中心(有限合夥)發起設立的蘇州工業園區元禾原點叁號醫療健康產業投資合夥企業(有限合夥)(“醫療叁號基金”),醫療叁號基金目標募集資金規模不低於人民幣5億元且不超過人民幣7.5億元,其中公司出資不超過2500萬元,且佔比不超過醫療叁號基金最終認繳總額的5%。
近日,醫療叁號基金已在中國證券投資基金業協會完成備案手續,並取得《私募投資基金備案證明》,基金名稱為蘇州工業園區元禾原點叁號醫療健康產業投資合夥企業(有限合夥)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.